Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Foghorn Therapeutics Inc. reported revenue of $31M, up 36.8% year over year. Operating margin was -279.5% and net margin -240.3%, on a free-cash-flow margin of -278.7% with capital expenditure at 0.2% of revenue. Every figure is computed directly from FHTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $31M | -279.5% | -240.3% |
| FY2024 | $23M | -454.3% | -383.2% |
| FY2023 | $34M | -315.9% | -288.2% |
| FY2022 | $19M | -609.2% | -566.3% |
| FY2021 | $1M | -7637.1% | -7681.6% |
How does FHTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.